Format

Send to

Choose Destination
PLoS One. 2015 Sep 14;10(9):e0136207. doi: 10.1371/journal.pone.0136207. eCollection 2015.

Double Relapsed and/or Refractory Multiple Myeloma: Clinical Outcomes and Real World Healthcare Costs.

Author information

1
Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE, United Kingdom; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, OX3 7LE, United Kingdom; MRC Human Immunology Unit, University of Oxford, Weatherall Institute of Molecular Medicine, Headley Way, Oxford, OX3 9DS, United Kingdom.
2
Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE, United Kingdom; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, OX3 7LE, United Kingdom.
3
Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE, United Kingdom; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, OX3 7LE, United Kingdom; Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford University Old Road Campus, Oxford, OX3 7LH, United Kingdom.
4
Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE, United Kingdom.
5
BresMed Health Solutions, 84 Queen Street, North Church House, Sheffield, S1 2DW, United Kingdom.
6
Department of Haematology, Oxford University Hospitals NHS Trust, Churchill Hospital, Old Road, Headington, Oxford, OX3 7LE, United Kingdom; National Institute for Health Research (NIHR) Oxford Biomedical Research Centre, Oxford University Hospitals NHS Trust, Oxford, OX3 7LE, United Kingdom; Royal Berkshire Hospital NHS Trust, London Rd, Reading, RG1 5AN, United Kingdom.

Abstract

Double relapsed and/or refractory multiple myeloma (DRMM), MM that is relapsed and/or refractory to bortezomib and lenalidomide, carries a poor prognosis. The healthcare costs of DRMM have not previously been reported. We analyzed detailed medical resource utilization (MRU) costs, drug costs and outcomes for 39 UK patients receiving standard DRMM therapy. Median OS in this cohort was 5.6 months. The mean cost of DRMM treatment plus MRU until death was £23,472 [range: £1,411-£90,262], split between drug costs £11,191 and other resource use costs £12,281. The cost per assumed quality-adjusted life year (QALY) during DRMM was £66,983. These data provide a standard of care comparison when evaluating the cost-effectiveness of new drugs in DRMM.

PMID:
26367874
PMCID:
PMC4569348
DOI:
10.1371/journal.pone.0136207
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Public Library of Science Icon for PubMed Central
Loading ...
Support Center